CGEM stock forecast
Our latest prediction for Cullinan Oncology Inc's stock price was made on the Dec. 29, 2023 when the stock price was at 10.19$.
In the short term (2weeks), CGEM's stock price should underperform the market by -3.30%. During that period the price should oscillate between -7.84% and +2.21%.
In the medium term (3months), CGEM's stock price should underperform the market by -6.18%. During that period the price should oscillate between -30.55% and +-1.75%.
Get email alertsCreate a solid portfolio with CGEM
About Cullinan Oncology Inc
cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
At the moment the company generates 24M USD in revenues.
On its last earning announcement, the company reported a loss of -3.69$ per share.
The book value per share is 5.61$
Three months stock forecastDec. 29, 2023
Financials
Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|---|---|---|
24M | - | -178M | - | -156M | -3.69 | - | - | 42M | 5.61 | - | - | - |